ADVM240621C5000
- 0.10
- 0.000.00%
Adverum Biotechnologies Newsroom
Adverum Biotechnologies Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Adverum Biotechnologies(ADVM.US) With Buy Rating, Announces Target Price $25
Oppenheimer analyst Francois Brisebois initiates coverage on $Adverum Biotechnologies(ADVM.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a succes
Express News | Adverum Biotechnologies Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $25
Adverum Biotechnologies to Participate in TD Cowen's Genetic Medicines & RNA Summit
Express News | Adverum Biotechnologies Announces Appointments of DR. Rabia Gurses Ozden as Chief Medical Officer and DR. Szilárd Kiss as a Member of the Board of Directors
Strong Buy Rating for Adverum Biotechnologies Amid Anticipated Positive Phase 2 Results and Market Undervaluation
Adverum Biotechnologies Is Maintained at Buy by Truist Securities
Truist Securities: Maintains Adverum Biotechnologies (ADVM.US) rating, adjusted from buy to buy rating, and adjusted target price from $60.00 to $60.00.
Truist Securities: Maintains Adverum Biotechnologies (ADVM.US) rating, adjusted from buy to buy rating, and adjusted target price from $60.00 to $60.00.
Truist Securities Maintains Buy on Adverum Biotechnologies, Maintains $60 Price Target
Adverum Biotechnologies (ADVM) Receives a Buy From Truist Financial
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
HC Wainwright & Co. Reiterates Buy on Adverum Biotechnologies, Maintains $30 Price Target
Adverum Biotechnologies (ADVM.US): The 2024 Q1 financial report achieved revenue of $0, previously $3.6 million; earnings per share were -1.50 dollars, previous value was -2.90 dollars, and expected value was -1.41 dollars.
Adverum Biotechnologies (ADVM.US): The 2024 Q1 financial report achieved revenue of $0, previously $3.6 million; earnings per share were -1.50 dollars, previous value was -2.90 dollars, and expected value was -1.41 dollars.
Adverum Biotechnologies Q1 2024 Adj EPS $(1.50) Misses $(1.40) Estimate
Adverum Biotechnologies | 10-Q: Quarterly report
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
Adverum Biotechnologies 1Q Loss/Shr $1.50 >ADVM
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
Adverum Biotechnologies a New Buy at H.C. Wainwright on Wet AMD Gene Therapy
Adverum Biotechnologies (ADVM.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $30.00.
Adverum Biotechnologies (ADVM.US) was first covered by HC Wainwright & Co. with a buy rating, with a target price of $30.00.